411 results match your criteria Asia-Pacific Oncology & Haematology [Journal]


Dual normative commitments mediating the relationship between perceived investment in employees' development and intention to leave among the healthcare workforce in underserviced areas of Taiwan.

Rural Remote Health 2019 Feb 7;19(1):4837. Epub 2019 Feb 7.

Department of Hematology-Oncology, E-Da Cancer Hospital, No. 21, Yi-Da Road, Jiao-Su Village, Yan-Chao District, 824, Kaohsiung City, Taiwan, Republic of China

Introduction: To study the factors affecting the intent to leave of healthcare workers who serve in underserviced areas of Taiwan, the authors tested the mediating role of both professional and organizational commitment in the relationship between perceived investment of employee development and intention to leave among these healthcare workers.

Method: This study was designed as a cross-sectional study using a well-organized questionnaire with major study variables consisting of perceived investment in employees' development (PIED), Meyer's occupational and organizational normative commitment, and intent to leave. In total, 692 healthcare workers from 48 health centers were enrolled for study; 616 people, including 415 (68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22605/RRH4837DOI Listing
February 2019

Standards of diagnostic colonoscopy for early-stage neoplasia: recommendations by an Asian private group.

Dig Endosc 2018 Dec 27. Epub 2018 Dec 27.

Department of Innovative Interventional Endoscopy Research, The Jikei University School of Medicine, Tokyo, Japan.

Background And Aim: In recent years, the incidence of colorectal cancer has been increasing, and it is now becoming the major cause of cancer death in Asian countries. The aim of this study was to develop Asian expert-based consensus to standardize the preparation, detection and characterization for diagnosis of early-stage colorectal neoplasia.

Methods: A professional group was formed by 36 expert the Asian Novel Bio-Imaging and Intervention Group (ANBI G) members. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/den.13330
Publisher Site
http://dx.doi.org/10.1111/den.13330DOI Listing
December 2018
11 Reads

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

JAMA Oncol 2018 Nov 1. Epub 2018 Nov 1.

Clinical Oncology, Cancer Center Centre Léon Bérard, University of Lyon, Lyon, France.

Importance: Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is unknown whether dual blockade can potentiate antitumor activity without compromising safety in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) and low or no PD-L1 tumor cell expression.

Objective: To assess safety and objective response rate of durvalumab combined with tremelimumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.4628DOI Listing
November 2018
6 Reads

NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4.

Authors:

Lancet 2018 09 20;392(10152):1072-1088. Epub 2018 Sep 20.

The third UN High-Level Meeting on Non-Communicable Diseases (NCDs) on Sept 27, 2018, will review national and global progress towards the prevention and control of NCDs, and provide an opportunity to renew, reinforce, and enhance commitments to reduce their burden. NCD Countdown 2030 is an independent collaboration to inform policies that aim to reduce the worldwide burden of NCDs, and to ensure accountability towards this aim. In 2016, an estimated 40·5 million (71%) of the 56·9 million worldwide deaths were from NCDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)31992-5DOI Listing
September 2018
5 Reads

Pediatric hepatocellular carcinoma.

World J Gastroenterol 2018 Sep;24(35):3980-3999

Department of Pediatrics, King George Medical University, Uttar Pradesh 226003, India.

Pediatric hepatocellular carcinoma (HCC) is the second common malignant liver tumor in children after hepatoblastoma. It differs from the adult HCC in the etiological predisposition, biological behavior and lower frequency of cirrhosis. Perinatally acquired hepatitis-B virus, hepatorenal tyrosinemia, progressive familial intrahepatic cholestasis, glycogen storage disease, Alagille's syndrome and congenital portosystemic shunts are important predisposing factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v24.i35.3980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148423PMC
September 2018
13 Reads

Soft tissue sarcoma in Asia.

Chin Clin Oncol 2018 Aug;7(4):46

Division of Medical Oncology, National Cancer Centre Singapore, Singapore.

Sarcoma is an uncommon and heterogeneous group of malignancies linked by their mesenchymal origin. They are rare and account for 1% of adult cancers, and 10-20% of adolescent and young adult (AYA) cancers. While there is good published literature on the incidence and distribution of sarcoma subtypes in the western populations, there is a paucity of data from Asia, particularly on the epidemiology, treatment and outcomes of STS in Asia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.08.06DOI Listing
August 2018
8 Reads

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Cancer Med 2018 Nov 19;7(11):5382-5393. Epub 2018 Aug 19.

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.

Background: The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib in patients with relapsed/refractory metastatic CRC.

Methods: In this two-part, multicenter, phase 2 study, eligible adult patients had metastatic adenocarcinoma of the colon or rectum; an Eastern Cooperative Oncology Group performance status of 0-2; received fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor therapy (if no contraindication); and if KRAS wild-type (and no contraindication), an anti-epidermal growth factor receptor therapy; and progressed following the last administration of approved therapy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cam4.1703
Publisher Site
http://dx.doi.org/10.1002/cam4.1703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246927PMC
November 2018
10 Reads

Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.

Future Oncol 2018 Aug 17;14(20):2031-2044. Epub 2018 Aug 17.

Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, PR China.

Aim: To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia-Pacific region (ClinicalTrials.gov: NCT01661270). Patients & methods: Asian patients with oxaliplatin-pretreated metastatic colorectal cancer were randomized to receive aflibercept or placebo, followed by FOLFIRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0669DOI Listing
August 2018
5 Reads

Impacts of demographic and laboratory parameters on key hematological indices in an adult population of southern Taiwan: A cohort study.

PLoS One 2018 2;13(8):e0201708. Epub 2018 Aug 2.

Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.

Studies in Caucasians have shown that values of hematological indices could be affected by a wide variety of factors. However, parallel work in other ethnical populations, particularly from the Asia-Pacific region, is lacking. Therefore, we designed this study to explore the association between clinical/laboratory parameters and hemogram levels. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201708PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072090PMC
February 2019
9 Reads

A survey of characteristics and current educational needs of hemophilia treatment centers within Asia Pacific.

Res Pract Thromb Haemost 2018 Jul 24;2(3):508-517. Epub 2018 May 24.

Department of Immunology and Pathology Monash University Melbourne Australia.

Background: Poor disease understanding and gaps in expertise regarding hemophilia care have been identified at all levels in Asia Pacific. Continued education for involved healthcare professionals (HCPs) is crucial for improved delivery.

Objectives: To identify training and educational needs of hemophilia HCPs in Asia Pacific. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rth2.12108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046602PMC
July 2018
2 Reads

A merged lung cancer transcriptome dataset for clinical predictive modeling.

Sci Data 2018 07 24;5:180136. Epub 2018 Jul 24.

NUS Graduate School for Integrative Sciences & Engineering (NGS), National University of Singapore, #05-01, 28 Medical Drive, Singapore 117456, Singapore.

The Gene Expression Omnibus (GEO) database is an excellent public source of whole transcriptomic profiles of multiple cancers. The main challenge is the limited accessibility of such large-scale genomic data to people without a background in bioinformatics or computer science. This presents difficulties in data analysis, sharing and visualization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sdata.2018.136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057440PMC
July 2018
5 Reads

Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.

BJU Int 2019 Jan 19;123(1):22-34. Epub 2018 Aug 19.

Monash University, Melbourne, VIC, Australia.

Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017).

Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14489DOI Listing
January 2019
10 Reads

Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.

EBioMedicine 2018 Jul 20;33:94-104. Epub 2018 Jun 20.

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:

Immunotherapeutic agents have demonstrated encouraging signs of clinical utility in non-Hodgkin lymphoma. The goal of this study is to analyze the immune characteristics of Chinese patients with diffuse large B-cell lymphoma (DLBCL) to inform the development of immunotherapies in this patient population. Tumor samples from 211 DLBCL patients were analyzed for cell of origin (COO) and immune characteristics using the NanoString platform as well as MYC protein expression through immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.06.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085499PMC
July 2018
18 Reads

PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.

Oncoimmunology 2018 20;7(6):e1433520. Epub 2018 Feb 20.

Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P. R. China.

Current studies aiming at identifying single immune markers with prognostic value have limitations in the context of complex antitumor immunity and cancer immune evasion. Here, we show how the integration of several immune markers influences the predictions of prognosis of gastric cancer (GC) patients. We analyzed Tissue Microarray (TMA) by multiplex immunohistochemistry and measured the expression of immune checkpoint molecule PD-L1 together with antitumor CD8 T cells and immune suppressive FOXP3 Treg cells in a cohort of GC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1433520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980489PMC
February 2018
12 Reads

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

J Clin Oncol 2018 Aug 4;36(22):2244-2250. Epub 2018 Jun 4.

Tony S. Mok, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Xiangdong Zhou, First Affiliated Hospital of Third Military Medical University, Chongqing; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; Ki Hyeong Lee, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; Kazuhiko Nakagawa, Kindai University Hospital, Osaka; Seiji Niho, National Cancer Center Hospital East, Kashiwa, Japan; Min Lee, SFJ Asia Pacific, Singapore; Rolf Linke, SFJ Pharmaceuticals Group, Pleasanton, CA; Rafael Rosell, Catalan Institute of Oncology, Barcelona; Jesus Corral, Hospital Universitario Virgen del Rocio, Seville, Spain; Maria Rita Migliorino, Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy; Adam Pluzanski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Eric I. Sbar, Pfizer, Collegeville, PA; Tao Wang and Jane Liang White, Pfizer, Groton, CT.

Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free survival with dacomitinib. The mature overall survival (OS) analysis for the intention-to-treat population is presented here. Patients and Methods In this multinational, multicenter study, patients age 18 years or older (≥ 20 years in Japan and Korea) who had an Eastern Cooperative Oncology Group performance status of 0 or 1 and newly diagnosed NSCLC with activating mutations in EGFR (exon 19 deletion or exon 21 L858R) were enrolled and randomly assigned in a 1:1 manner to dacomitinib (n = 227) or gefitinib (n = 225). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7994DOI Listing
August 2018
41 Reads

A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis.

Reprod Health 2018 May 10;15(1):77. Epub 2018 May 10.

Department of Gastroenterology, Changzhou No. 2 Hospital, Affiliated with Nanjing Medical University, Changzhou, 213000, China.

Background: Epidemiological literature regarding the effect of polycystic ovary syndrome (PCOS) as a risk factor for non-alcoholic fatty liver disease (NAFLD) remains inconsistent. Furthermore, it remains debatable whether NAFLD is associated with PCOS as a consequence of shared risk factors or whether PCOS contributes to NAFLD in an independent fashion. Therefore, this meta-analysis was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12978-018-0519-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946415PMC
May 2018
3 Reads

Vemurafenib in Chinese patients with BRAF mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.

BMC Cancer 2018 May 3;18(1):520. Epub 2018 May 3.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52# Fucheng Road, Haidian District, Beijing, 100142, China.

Background: Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAF kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. Limited data are available regarding the efficacy and safety of vemurafenib in Asian patients. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-4336-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934791PMC
May 2018
6 Reads

Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.

Nat Commun 2018 04 30;9(1):1725. Epub 2018 Apr 30.

Samsung Biological Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea.

Breast cancer (BC) in the Asia Pacific regions is enriched in younger patients and rapidly rising in incidence yet its molecular bases remain poorly characterized. Here we analyze the whole exomes and transcriptomes of 187 primary tumors from a Korean BC cohort (SMC) enriched in pre-menopausal patients and perform systematic comparison with a primarily Caucasian and post-menopausal BC cohort (TCGA). SMC harbors higher proportions of HER2+ and Luminal B subtypes, lower proportion of Luminal A with decreased ESR1 expression compared to TCGA. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-04129-4
Publisher Site
http://dx.doi.org/10.1038/s41467-018-04129-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928087PMC
April 2018
17 Reads

The Tsinghua-Lancet Commission on Healthy Cities in China: unlocking the power of cities for a healthy China.

Lancet 2018 05 17;391(10135):2140-2184. Epub 2018 Apr 17.

Ministry of Education Key Laboratory for Earth System Modeling, Department of Earth System Science, Tsinghua University, Beijing, China; Joint Center for Global Change Studies (JCGCS), Beijing, China; Center for Healthy Cities, Institute for China Sustainable Urbanization, Tsinghua University, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30486-0DOI Listing
May 2018
14 Reads
1 Citation
45.220 Impact Factor

Gaining Insights on Nasopharyngeal Carcinoma Treatment Outcome Using Clinical Data Mining Techniques.

Stud Health Technol Inform 2018 ;247:386-390

Asia Pacific University.

The analysis of Electronic Health Records (EHRs) is attracting a lot of research attention in the medical informatics domain. Hospitals and medical institutes started to use data mining techniques to gain new insights from the massive amounts of data that can be made available through EHRs. Researchers in the medical field have often used descriptive statistics and classical statistical methods to prove assumed medical hypotheses. Read More

View Article

Download full-text PDF

Source
June 2018
5 Reads

Highlights of the Third Expert Forum of Asia-Pacific Laparoscopic Hepatectomy; Endoscopic and Laparoscopic Surgeons of Asia (ELSA) Visionary Summit 2017.

Ann Hepatobiliary Pancreat Surg 2018 Feb 26;22(1):1-10. Epub 2018 Feb 26.

Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

The application of laparoscopy for liver surgery is rapidly increasing and the past few years have demonstrated a shift in paradigm with a trend towards more extended and complex resections. The development of instruments and technical refinements with the effective use of magnified caudal laparoscopic views have contributed to the ability to overcome the limitation of laparoscopic liver resection. The Endoscopic and Laparoscopic Surgeons of Asia (ELSA) Visionary Summit 2017 and the 3 Expert Forum of Asia-Pacific Laparoscopic Hepatectomy organized hepatobiliary pancreatic sessions in order to exchange surgical tips and tricks and discuss the current status and future perspectives of laparoscopic hepatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14701/ahbps.2018.22.1.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845605PMC
February 2018
15 Reads

Correction to: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study.

BMC Cancer 2018 03 1;18(1):240. Epub 2018 Mar 1.

School of Nursing, Hong Kong Polytechnic University, Hong Kong, China.

It has been highlighted that the original manuscript [1] contains a typesetting error in the surname of Jesson Butcon. This was incorrectly captured as Jessica Butcon in the original manuscript which has since been updated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4105-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833088PMC
March 2018
15 Reads

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Lancet 2018 03;391(10126):1163-1173

National Taiwan University Hospital, Taipei, Taiwan.

Background: In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma.

Methods: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30207-1DOI Listing
March 2018
28 Reads

Use of Social Media and an Online Survey to Discuss Complex Reconstructive Surgery: A Case of Upper Lip Reconstruction with 402 Responses from International Microsurgeons.

J Reconstr Microsurg 2018 Jul 2;34(6):413-419. Epub 2018 Feb 2.

Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Linkou Medical Center and Chang Gung Medical College and Chang Gung University, Taoyuan, Taiwan.

Background:  The best reconstructive strategy for upper lip defects is still in debate. The purpose of this study was to analyze the decisions made by international microsurgeons, who were participated through online questionnaire, distributed by email and social media network.

Materials And Methods:  A case of a two-thirds upper lip oncologic defect was presented via an online questionnaire and 402 microsurgeons replied their treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1626696DOI Listing
July 2018
10 Reads

Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation.

Oncotarget 2017 Dec 28;8(70):114526-114539. Epub 2017 Sep 28.

Sanofi Oncology Therapeutic Area, Cambridge, MA, USA.

Hepatocellular carcinoma (HCC) represents a serious public health challenge with few therapeutic options available to cancer patients.Wnt/β-catenin pathway is thought to play a significant role in HCC pathogenesis. In this study, we confirmed high frequency of CTNNB1 (β-catenin) mutations in two independent cohorts of HCC patients and demonstrated significant upregulation of β-catenin protein in the overwhelming majority of HCC patient samples, patient-derived xenografts (PDX) and established cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777711PMC
December 2017
8 Reads

Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.

Lung Cancer 2018 01 28;115:121-126. Epub 2017 Nov 28.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, PR China. Electronic address:

Objectives: In the JMEN trial, patients with advanced non-squamous non-small cell lung cancer (NSCLC) without progression after platinum-based first-line therapy derived extended survival, delayed disease progression, and maintained overall quality of life (QoL) from pemetrexed maintenance therapy. However, fatigue was the most common physician-reported non-hematological toxicity in the pemetrexed group. This post hoc analysis investigated dynamic change of fatigue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.11.026DOI Listing
January 2018
4 Reads

Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

Cancer Sci 2018 Mar 8;109(3):771-776. Epub 2018 Feb 8.

Seoul National University College of Medicine, Seoul, Korea.

KEYNOTE-012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia-Pacific region are reported. Patients with recurrent/metastatic HNSCC, measurable disease (RECIST version 1. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13480
Publisher Site
http://dx.doi.org/10.1111/cas.13480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834807PMC
March 2018
27 Reads

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Lancet 2018 02 18;391(10122):748-757. Epub 2017 Dec 18.

Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.

Background: Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population.

Methods: We conducted this multicentre, open-label, phase 3 randomised controlled trial (IMvigor211) at 217 academic medical centres and community oncology practices mainly in Europe, North America, and the Asia-Pacific region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)33297-XDOI Listing
February 2018
56 Reads
8 Citations
45.220 Impact Factor

Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting.

Liver Cancer 2017 Nov 30;6(4):264-274. Epub 2017 Aug 30.

Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.

Background: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/475768
Publisher Site
http://dx.doi.org/10.1159/000475768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704685PMC
November 2017
10 Reads

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.

Cancer Immunol Immunother 2018 Mar 6;67(3):471-481. Epub 2017 Dec 6.

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhong-shan Er Road, Guangzhou, 510030, China.

The goal of this study is to evaluate PD-L1 prevalence and its association with major clinical characteristics in Chinese non-small cell lung cancer (NSCLC) patients to inform the clinical development of anti-PD1/PD-L1 agents in this population. We used phosphatase and tensin homolog (PTEN) expression through IHC as a surrogate tissue quality marker to screen surgical NSCLC samples in tissue microarray (TMA; 172 cases) or whole-section (268 cases) format. The samples were then analyzed with a clinically validated PD-L1 IHC assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2098-4DOI Listing
March 2018
50 Reads

Defining a global research and policy agenda for betel quid and areca nut.

Lancet Oncol 2017 12;18(12):e767-e775

National Cancer Institute, National Institutes of Health, Rockville, MA, USA.

Betel quid and areca nut are known risk factors for many oral and oesophageal cancers, and their use is highly prevalent in the Asia-Pacific region. Additionally, betel quid and areca nut are associated with health effects on the cardiovascular, nervous, gastrointestinal, metabolic, respiratory, and reproductive systems. Unlike tobacco, for which the WHO Framework Convention on Tobacco Control provides evidence-based policies for reducing tobacco use, no global policy exists for the control of betel quid and areca nut use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30460-6DOI Listing
December 2017
8 Reads

A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.

Dig Liver Dis 2018 Mar 15;50(3):254-259. Epub 2017 Nov 15.

Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: We aimed to develop a combination screening strategy for advanced colorectal neoplasia based on the Asia-Pacific Colorectal Screening score and fecal immunochemical test results.

Methods: We reviewed the records of participants who had undergone a colonoscopy and fecal immunochemical test as part of a comprehensive health screening program. The prevalence of advanced colorectal neoplasia in participants 40-49 years old was analyzed according to Asia-Pacific Colorectal Screening scores and fecal immunochemical test results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2017.11.002DOI Listing
March 2018
9 Reads

An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer.

Nat Commun 2017 11 23;8(1):1734. Epub 2017 Nov 23.

NUS Graduate School for Integrative Sciences & Engineering (NGS), National University of Singapore, #05-01, 28 Medical Drive, Singapore, 117456, Singapore.

The prognosis and prediction of adjuvant chemotherapy (ACT) response in early-stage non-small cell lung cancer (NSCLC) patients remain poor in this era of personalized medicine. We hypothesize that extracellular matrix (ECM)-associated components could be potential markers for better diagnosis and prognosis due to their differential expression in 1,943 primary NSCLC tumors as compared to 303 normal lung tissues. Here we develop a 29-gene ECM-related prognostic and predictive indicator (EPPI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-01430-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700969PMC
November 2017
4 Reads

DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.

Cancer Chemother Pharmacol 2018 01 13;81(1):119-129. Epub 2017 Nov 13.

Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh.

Background: Significant inter-individual variation in the sensitivity to 5-fluorouracil (5-FU) represents a major therapeutic hindrance either by impairing drug response or inducing adverse drug reactions (ADRs). This study aimed at exploring the cause behind this inter-individual alterations in consequences of 5-fluorouracil-based chemotherapy by investigating the effects of DPYD*2A and MTHFR C677T polymorphisms on toxicity and response of 5-FU in Bangladeshi colorectal cancer patients.

Methods: Colorectal cancer patients (n = 161) receiving 5-FU-based chemotherapy were prospectively enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3478-3DOI Listing
January 2018
26 Reads
2.770 Impact Factor

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.

Lung Cancer 2017 11 1;113:37-44. Epub 2017 Sep 1.

Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Centre for Lung Research (DZL), Wöhrendamm 80, Grosshansdorf, 22927, Germany.

Objectives: Limited understanding exists of epidermal growth factor receptor (EGFR) mutation frequency in less common subgroups of advanced non-small-cell lung cancer (aNSCLC) (e.g. squamous cell carcinoma [SCC]), and to what extent local practices exclude patients from EGFR testing based on their clinical characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.021DOI Listing
November 2017
29 Reads

Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study.

BMC Cancer 2017 Nov 6;17(1):715. Epub 2017 Nov 6.

School of Nursing, Hong Kong Polytechnic University, Hong Kong, China.

Background: Most efforts to advance cancer survivorship care have occurred in Western countries. There has been limited research towards gaining a comprehensive understanding of survivorship care provision in the Asia-Pacific region. This study aimed to establish the perceptions of responsibility, confidence, and frequency of survivorship care practices of oncology practitioners and examine their perspectives on factors that impede quality survivorship care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3733-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674781PMC
November 2017
15 Reads

Genetic variants of SULT1A1 and XRCC1 genes and risk of lung cancer in Bangladeshi population.

Tumour Biol 2017 Nov;39(11):1010428317729270

1 Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh.

Lung cancer is one of the most frequently occurring cancers throughout the world as well as in Bangladesh. This study aimed to correlate the prognostic and/or predictive value of functional polymorphisms in SULT1A1 (rs9282861) and XRCC1 (rs25487) genes and lung cancer risk in Bangladeshi population. A case-control study was conducted which comprises 202 lung cancer patients and 242 healthy volunteers taking into account the age, sex, and smoking status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1010428317729270DOI Listing
November 2017
27 Reads
2.840 Impact Factor

Differentiation of hypointense nodules on gadoxetic acid-enhanced hepatobiliary-phase MRI using T enhanced spin-echo imaging with the time-reversed gradient echo sequence: An initial experience.

Eur J Radiol 2017 Oct 30;95:325-331. Epub 2017 Aug 30.

Philips Healthcare Asia Pacific, 2-13-37 Kounan, Minato-ku, Tokyo 108-8507, Japan.

Purpose: To optimize the flip angle (FA) of the T enhanced spin-echo imaging using the time reversed gradient echo (T2FFE) and evaluate its utility for differentiating hypointensity nodules in the hepatobiliary phase (HBP) of gadoxetic acid-enhanced (Gd-EOB) MRI.

Materials And Methods: First, FA optimization of the T2FFE in the HBP was investigated by comparing signal-to-noise ratio (SNR) among different FAs using phantoms. The liver-to-muscle contrast ratios (CR) and image quality among three FAs (20°, 50° and 80°) were compared using images of 10 patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0720048X173034
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2017.08.025DOI Listing
October 2017
34 Reads

Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study.

Ann Oncol 2017 Oct;28(10):2552-2558

School of Nursing, Queensland University of Technology, Brisbane.

Background: To assess the supportive care needs, quality of life (QoL) and symptoms of patients with cancer after the end of first-line treatments and into survivorship in Asian countries using Australian data as benchmark.

Patients And Methods: A cross-sectional survey was carried out in Australia and eight high-income (HICs) and low-/middle-income (LMICs) Asian countries (China, Japan, Hong Kong SAR, South Korea, Myanmar, Thailand, India, Philippines) using validated scales (Cancer Survivors Unmet Needs scale), physical-symptom concerns (Cancer Survivors Survey of Needs subscale) and a single-item measure of global QoL perception.

Results: Data were collected from 1748 patients from nine countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdx350DOI Listing
October 2017
5 Reads

Environmental contributions to gastrointestinal and liver cancer in the Asia-Pacific region.

J Gastroenterol Hepatol 2018 Jan;33(1):111-120

Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.

In the Asia-Pacific region, gastric, colorectal, and hepatocellular (liver) cancer show substantial regional variation in incidence consistent with the presence of important environmental factors. For gastric cancer, global incidence is concentrated in Asia with substantially higher rates in East Asia than in South-East Asia and Australia. The differences in incidence rates for gastric cancer in the Asia-Pacific region may be due, in part, to differences in the prevalence of Helicobacter pylori infection and the prevalence of H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14005DOI Listing
January 2018
9 Reads

Significance of UICC Activities in Global Health Initiatives on Cancer Looking Towards the Future of Cooperative Networks for Cancer Care in Asia - A Dialogue with the Union for International Cancer Control(UICC).

Gan To Kagaku Ryoho 2017 Sep;44(9):757-761

The University of Tokyo.

At the 24th Asia Pacific Cancer Conference held in Seoul, Korea from 22 to 24 June 2017, a dialogue with Dr.Cary Adams, CEO of the Union for International Cancer Control(UICC)was held to discuss the significance of UICC activities in global health initiatives on cancer and pathways for cooperation on cancer control and care.UICC is engaged in a wide range of capacity building, advocacy and convening initiatives and is increasingly focusing on multi-sectoral approaches. Read More

View Article

Download full-text PDF

Source
September 2017
4 Reads

Diagnostic accuracy of pre-treatment biopsy for grading cutaneous mast cell tumours in dogs.

Vet Comp Oncol 2018 Jun 31;16(2):214-219. Epub 2017 Aug 31.

Faculty of Veterinary and Agricultural Sciences, Asia-Pacific Centre for Animal Health, The University of Melbourne, Parkville, Victoria, Australia.

Mast cell tumours (MCTs) are common tumours of the canine skin, and are estimated to represent up to 20% of all skin tumours in dogs. Tumour grade has a major impact on the incidence of local recurrence and metastatic potential. In addition to helping the clinician with surgical planning, knowledge of the tumour grade also assists in proper prognostication and client education. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vco.12346DOI Listing
June 2018
6 Reads

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Lancet Oncol 2017 10 23;18(10):1327-1337. Epub 2017 Aug 23.

Hematology Department, University of Nantes, Nantes, France.

Background: The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30578-8DOI Listing
October 2017
72 Reads

A prediction model for advanced colorectal neoplasia in an asymptomatic screening population.

PLoS One 2017 25;12(8):e0181040. Epub 2017 Aug 25.

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: An electronic medical record (EMR) database of a large unselected population who received screening colonoscopies may minimize sampling error and represent real-world estimates of risk for screening target lesions of advanced colorectal neoplasia (CRN). Our aim was to develop and validate a prediction model for assessing the probability of advanced CRN using a clinical data warehouse.

Methods: A total of 49,450 screenees underwent their first colonoscopy as part of a health check-up from 2002 to 2012 at Samsung Medical Center, and the dataset was constructed by means of natural language processing from the computerized EMR system. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181040PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571924PMC
October 2017
13 Reads

Impact of Age on the Risk of Advanced Colorectal Neoplasia in a Young Population: An Analysis Using the Predicted Probability Model.

Dig Dis Sci 2017 09 21;62(9):2518-2525. Epub 2017 Jul 21.

Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29, Saemunan-Ro, Jongno-Gu, Seoul, 03181, Republic of Korea.

Background: The incidence of colorectal cancer is decreasing in adults aged ≥50 years and increasing in those aged <50 years.

Aims: We aimed to establish risk stratification model for advanced colorectal neoplasia (ACRN) in persons aged <50 years.

Methods: We reviewed the records of participants who had undergone a colonoscopy as part of a health examination at two large medical examination centers in Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-017-4683-yDOI Listing
September 2017
30 Reads

Noninvasive electrical conductivity measurement by MRI: a test of its validity and the electrical conductivity characteristics of glioma.

Eur Radiol 2018 Jan 11;28(1):348-355. Epub 2017 Jul 11.

Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Japan.

Objectives: This study noninvasively examined the electrical conductivity (σ) characteristics of diffuse gliomas using MRI and tested its validity.

Methods: MRI including a 3D steady-state free precession (3D SSFP) sequence was performed on 30 glioma patients. The σ maps were reconstructed from the phase images of the 3D SSFP sequence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-017-4942-5DOI Listing
January 2018
24 Reads

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

J Hepatol 2017 11 4;67(5):999-1008. Epub 2017 Jul 4.

Hepatic Oncology, BCLC Hospital Clínic Barcelona, IDIBAPS, University of Barcelona CIBERehd, Barcelona, Spain; Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

Background & Aims: Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase III studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific (AP). To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we conducted a pooled exploratory analysis from these placebo-controlled phase III studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2017.06.026DOI Listing
November 2017
59 Reads